Lipidomics of Alzheimer's disease. (February 2014)

• Record Type: Journal Article
• Authors: Touboul, David; Gaudin, Mathieu
• Is Part Of: Bioanalysis. Volume 6:Number 4(2014)
• Page Start: 541
• Page End: 561
• Publication Date: 2014-02
• Subjects: Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio.13.346
• Languages: English
• ISSNs: 1757-6180

Abstract

Alzheimer's disease (AD) is a progressive brain disease that leads to an irreversible loss of neurons and cognition. It is the most common cause of dementia and can be considered as a major public health problem. At the histological level, AD is characterized by senile plaques and neurofibrillary tangles. Numerous studies involving genomic, transcriptomic and proteomic approaches have been published in order to understand the molecular mechanisms involved in AD, and to find new biomarkers. Metabolomics, and in particular lipidomics, have recently offered new possibilities due to the development of robust and sensitive analytical methods, such as LC–MS. This review aims to illustrate how lipidomics can help understand the biological mechanisms inherent to AD and how lipids can be considered as relevant biomarkers of AD at early stages.